Access cutting-edge dry eye syndrome treatment through this clinical trial at a research site in Harlingen. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Harlingen location
Preparing your pre-screening questions…
Access dry eye syndrome specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related dry eye syndrome treatment provided free
Check if you qualify for this dry eye syndrome clinical trial in Harlingen, TX
No-Cost Study Care
Local to Harlingen
Convenient for TX residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity and Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement. ABBV-319 exhibits potential B cell depletion in SLE and SjD which are characterized by B cell hyperactivity. The purpose of this study is to assess the pharmacokinetics, safety, and efficacy of ABBV-319 in adult participants with SLE or SjD. ABBV-319 is an investigational drug being developed for the treatment of SLE and SjD. Participants are placed in 1 of 6 groups called treatment arms. Each group receives a different dose of ABBV-319 depending on whether they have SLE or SjD. Around 36 adult participants with SLE or SjD will be enrolled at approximately 10 sites worldwide. Participants will receive 2 doses of IV ABBV-319 21 days apart and will be followed for up to 343 days. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Sponsor: AbbVie
Yes, this clinical trial (NCT06977724) has an active research site in Harlingen, TX that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for dry eye syndrome treatment options in Harlingen, TX, this clinical trial (NCT06977724) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Harlingen research site is actively enrolling participants for this clinical trial. You'll receive care from experienced dry eye syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all dry eye syndrome clinical trials near you to find additional studies recruiting in your area.
See all sjogrens syndrome clinical trials recruiting in Harlingen — not just this study.
Browse Sjogrens Syndrome Trials in Harlingen →